Do analysts recommend TAK or NVO?

Novo Nordisk A/S has a consensus price target of $65.56, suggesting a potential upside of 36.56%. Given Novo Nordisk A/S's higher possible upside, analysts plainly believe Novo Nordisk A/S is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Novo Nordisk A/S 1 Sell rating(s) 17 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.17

Does the media refer more to TAK or NVO?

In the previous week, Novo Nordisk A/S had 21 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 25 mentions for Novo Nordisk A/S and 4 mentions for Takeda Pharmaceutical. Novo Nordisk A/S's average media sentiment score of 0.85 beat Takeda Pharmaceutical's score of 0.12 indicating that Novo Nordisk A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Novo Nordisk A/S 17 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive

Do analysts prefer SNY or TAK?

Sanofi currently has a consensus price target of $51.00, suggesting a potential upside of 18.74%. Given Sanofi's higher possible upside, research analysts clearly believe Sanofi is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sanofi 0 Sell rating(s) 10 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 2.47 Takeda Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50

Does the media favor SNY or TAK?

In the previous week, Sanofi had 4 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 8 mentions for Sanofi and 4 mentions for Takeda Pharmaceutical. Sanofi's average media sentiment score of 0.51 beat Takeda Pharmaceutical's score of 0.12 indicating that Sanofi is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanofi 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Takeda Pharmaceutical 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer TAK or GSK?

GSK has a consensus price target of $53.00, suggesting a potential upside of 0.96%. Given GSK's higher possible upside, analysts plainly believe GSK is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 GSK 3 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation and earnings, TAK or GSK?

GSK has higher revenue and earnings than Takeda Pharmaceutical. GSK is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Takeda Pharmaceutical $28.32B 1.79 -$1.01B $0.39 40.81 GSK $43.07B 2.47 $7.54B $3.85 13.63

Does the media favor TAK or GSK?

In the previous week, GSK had 2 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 6 mentions for GSK and 4 mentions for Takeda Pharmaceutical. GSK's average media sentiment score of 1.26 beat Takeda Pharmaceutical's score of 0.12 indicating that GSK is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral GSK 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer TAK or ARGX?

argenex has a consensus target price of $1,023.39, suggesting a potential upside of 15.35%. Given argenex's stronger consensus rating and higher probable upside, analysts clearly believe argenex is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 argenex 0 Sell rating(s) 4 Hold rating(s) 18 Buy rating(s) 2 Strong Buy rating(s) 2.92

Does the media refer more to TAK or ARGX?

In the previous week, argenex had 8 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 12 mentions for argenex and 4 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.12 beat argenex's score of 0.00 indicating that Takeda Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral argenex 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate TAK or TEVA?

Teva Pharmaceutical Industries has a consensus target price of $41.78, indicating a potential upside of 25.68%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Teva Pharmaceutical Industries 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.80

Takeda Pharmaceutical (TAK) Competitors

$15.92 +0.27 (+1.69%)

Closing price 06/26/2026 03:59 PM Eastern

Extended Trading

$15.92 +0.01 (+0.06%)

As of 06/26/2026 04:10 PM Eastern

Compare

TAK vs. NVO, SNY, GSK, ARGX, and TEVA

Should you buy Takeda Pharmaceutical stock or one of its competitors? MarketBeat compares Takeda Pharmaceutical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Takeda Pharmaceutical include Novo Nordisk A/S (NVO), Sanofi (SNY), GSK (GSK), argenex (ARGX), and Teva Pharmaceutical Industries (TEVA). These companies are all part of the "pharmaceutical products" industry.

How does Takeda Pharmaceutical compare to Novo Nordisk A/S?

Takeda Pharmaceutical (NYSE:TAK) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by company insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Takeda Pharmaceutical pays an annual dividend of $0.25 per share and has a dividend yield of 1.6%. Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 3.6%. Takeda Pharmaceutical pays out 64.1% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 41.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

Novo Nordisk A/S has a consensus price target of $65.56, suggesting a potential upside of 36.56%. Given Novo Nordisk A/S's higher possible upside, analysts plainly believe Novo Nordisk A/S is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Novo Nordisk A/S	1 Sell rating(s)	17 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.17

Takeda Pharmaceutical has a beta of -0.07, meaning that its share price is 107% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market.

In the previous week, Novo Nordisk A/S had 21 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 25 mentions for Novo Nordisk A/S and 4 mentions for Takeda Pharmaceutical. Novo Nordisk A/S's average media sentiment score of 0.85 beat Takeda Pharmaceutical's score of 0.12 indicating that Novo Nordisk A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Novo Nordisk A/S	17 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

Novo Nordisk A/S has higher revenue and earnings than Takeda Pharmaceutical. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.32B	1.79	-$1.01B	$0.39	40.81
Novo Nordisk A/S	$46.80B	4.58	$15.51B	$4.26	11.27

Novo Nordisk A/S has a net margin of 37.23% compared to Takeda Pharmaceutical's net margin of 4.31%. Novo Nordisk A/S's return on equity of 63.31% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	4.31%	11.20%	5.48%
Novo Nordisk A/S	37.23%	63.31%	22.19%

Summary

Novo Nordisk A/S beats Takeda Pharmaceutical on 16 of the 18 factors compared between the two stocks.

How does Takeda Pharmaceutical compare to Sanofi?

Sanofi (NASDAQ:SNY) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

In the previous week, Sanofi had 4 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 8 mentions for Sanofi and 4 mentions for Takeda Pharmaceutical. Sanofi's average media sentiment score of 0.51 beat Takeda Pharmaceutical's score of 0.12 indicating that Sanofi is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.1%. Takeda Pharmaceutical pays an annual dividend of $0.25 per share and has a dividend yield of 1.6%. Sanofi pays out 49.2% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 64.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Sanofi is clearly the better dividend stock, given its higher yield and lower payout ratio.

Sanofi has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.07, indicating that its share price is 107% less volatile than the broader market.

Sanofi has higher revenue and earnings than Takeda Pharmaceutical. Sanofi is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$49.35B	2.11	$8.84B	$3.58	12.00
Takeda Pharmaceutical	$28.32B	1.79	-$1.01B	$0.39	40.81

Sanofi has a net margin of 16.95% compared to Takeda Pharmaceutical's net margin of 4.31%. Sanofi's return on equity of 13.39% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	16.95%	13.39%	7.58%
Takeda Pharmaceutical	4.31%	11.20%	5.48%

Sanofi currently has a consensus price target of $51.00, suggesting a potential upside of 18.74%. Given Sanofi's higher possible upside, research analysts clearly believe Sanofi is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

14.0% of Sanofi shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 1.0% of Sanofi shares are held by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Sanofi beats Takeda Pharmaceutical on 17 of the 19 factors compared between the two stocks.

How does Takeda Pharmaceutical compare to GSK?

Takeda Pharmaceutical (NYSE:TAK) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

In the previous week, GSK had 2 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 6 mentions for GSK and 4 mentions for Takeda Pharmaceutical. GSK's average media sentiment score of 1.26 beat Takeda Pharmaceutical's score of 0.12 indicating that GSK is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
GSK	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Takeda Pharmaceutical pays an annual dividend of $0.25 per share and has a dividend yield of 1.6%. GSK pays an annual dividend of $1.81 per share and has a dividend yield of 3.4%. Takeda Pharmaceutical pays out 64.1% of its earnings in the form of a dividend. GSK pays out 47.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.

GSK has higher revenue and earnings than Takeda Pharmaceutical. GSK is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.32B	1.79	-$1.01B	$0.39	40.81
GSK	$43.07B	2.47	$7.54B	$3.85	13.63

Takeda Pharmaceutical has a beta of -0.07, indicating that its share price is 107% less volatile than the broader market. Comparatively, GSK has a beta of 0.36, indicating that its share price is 64% less volatile than the broader market.

GSK has a consensus price target of $53.00, suggesting a potential upside of 0.96%. Given GSK's higher possible upside, analysts plainly believe GSK is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
GSK	3 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.00

GSK has a net margin of 17.82% compared to Takeda Pharmaceutical's net margin of 4.31%. GSK's return on equity of 44.28% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	4.31%	11.20%	5.48%
GSK	17.82%	44.28%	11.49%

9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 15.7% of GSK shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by insiders. Comparatively, 10.0% of GSK shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

GSK beats Takeda Pharmaceutical on 16 of the 18 factors compared between the two stocks.

How does Takeda Pharmaceutical compare to argenex?

Takeda Pharmaceutical (NYSE:TAK) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

argenex has lower revenue, but higher earnings than Takeda Pharmaceutical. argenex is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.32B	1.79	-$1.01B	$0.39	40.81
argenex	$4.25B	12.99	$1.29B	$22.46	39.50

argenex has a consensus target price of $1,023.39, suggesting a potential upside of 15.35%. Given argenex's stronger consensus rating and higher probable upside, analysts clearly believe argenex is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

In the previous week, argenex had 8 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 12 mentions for argenex and 4 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.12 beat argenex's score of 0.00 indicating that Takeda Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
argenex	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Takeda Pharmaceutical has a beta of -0.07, indicating that its share price is 107% less volatile than the broader market. Comparatively, argenex has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market.

9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 60.3% of argenex shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by insiders. Comparatively, 2.4% of argenex shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

argenex has a net margin of 31.31% compared to Takeda Pharmaceutical's net margin of 4.31%. argenex's return on equity of 44.37% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	4.31%	11.20%	5.48%
argenex	31.31%	44.37%	37.55%

Summary

argenex beats Takeda Pharmaceutical on 14 of the 17 factors compared between the two stocks.

How does Takeda Pharmaceutical compare to Teva Pharmaceutical Industries?

Takeda Pharmaceutical (NYSE:TAK) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

Teva Pharmaceutical Industries has lower revenue, but higher earnings than Takeda Pharmaceutical. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.32B	1.79	-$1.01B	$0.39	40.81
Teva Pharmaceutical Industries	$17.26B	2.21	$1.41B	$1.33	24.99

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Takeda Pharmaceutical's net margin of 4.31%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	4.31%	11.20%	5.48%
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%

Takeda Pharmaceutical has a beta of -0.07, indicating that its stock price is 107% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

Teva Pharmaceutical Industries has a consensus target price of $41.78, indicating a potential upside of 25.68%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Teva Pharmaceutical Industries had 10 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 14 mentions for Teva Pharmaceutical Industries and 4 mentions for Takeda Pharmaceutical. Teva Pharmaceutical Industries' average media sentiment score of 1.27 beat Takeda Pharmaceutical's score of 0.12 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Teva Pharmaceutical Industries	11 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Teva Pharmaceutical Industries beats Takeda Pharmaceutical on 14 of the 16 factors compared between the two stocks.

Get Takeda Pharmaceutical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TAK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TAK vs. The Competition

Export

Metric	Takeda Pharmaceutical	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$50.63B	$3.04B	$7.04B	$23.32B
Dividend Yield	1.58%	1.77%	2.66%	4.07%
P/E Ratio	40.81	19.54	26.13	31.64
Price / Sales	1.79	330.40	556.13	21.37
Price / Cash	5.13	57.21	47.95	24.80
Price / Book	1.03	4.21	10.78	4.74
Net Income	-$1.01B	$64.45M	$3.58B	$1.07B
7 Day Performance	1.79%	2.22%	2.22%	0.99%
1 Month Performance	-1.55%	-0.77%	-0.09%	0.46%
1 Year Performance	5.36%	29.70%	34.39%	25.30%

Takeda Pharmaceutical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TAK Takeda Pharmaceutical	2.5251 of 5 stars	$15.92 +1.7%	N/A	+5.4%	$50.63B	$28.32B	40.81	47,455	News Coverage Analyst Downgrade
NVO Novo Nordisk A/S	4.1912 of 5 stars	$45.90 +6.3%	$65.56 +42.8%	-29.9%	$192.84B	$46.80B	10.77	69,505
SNY Sanofi	4.3937 of 5 stars	$41.78 -1.4%	$51.00 +22.1%	-10.2%	$102.75B	$49.35B	11.67	74,846	High Trading Volume
GSK GSK	3.2165 of 5 stars	$50.70 +0.1%	$53.00 +4.5%	+36.2%	$102.61B	$43.07B	13.18	66,841	Positive News Dividend Cut Analyst Upgrade
ARGX argenex	4.1987 of 5 stars	$903.75 +3.0%	$1,019.50 +12.8%	+58.4%	$54.58B	$4.25B	40.24	1,863	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:TAK) was last updated on 6/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Takeda Pharmaceutical (TAK) Competitors

TAK vs. NVO, SNY, GSK, ARGX, and TEVA

How does Takeda Pharmaceutical compare to Novo Nordisk A/S?

Summary

How does Takeda Pharmaceutical compare to Sanofi?

Summary

How does Takeda Pharmaceutical compare to GSK?

Summary

How does Takeda Pharmaceutical compare to argenex?

Summary

How does Takeda Pharmaceutical compare to Teva Pharmaceutical Industries?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TAK vs. The Competition

Takeda Pharmaceutical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Takeda Pharmaceutical (TAK) Competitors

TAK vs. NVO, SNY, GSK, ARGX, and TEVA

How does Takeda Pharmaceutical compare to Novo Nordisk A/S?

Do insiders and institutionals have more ownership in TAK or NVO?

Is TAK or NVO a better dividend stock?

Do analysts recommend TAK or NVO?

Which has more risk & volatility, TAK or NVO?

Does the media refer more to TAK or NVO?

Which has stronger valuation and earnings, TAK or NVO?

Is TAK or NVO more profitable?

Summary

How does Takeda Pharmaceutical compare to Sanofi?

Does the media favor SNY or TAK?

Is SNY or TAK a better dividend stock?

Which has more volatility & risk, SNY or TAK?

Which has stronger earnings and valuation, SNY or TAK?

Is SNY or TAK more profitable?

Do analysts prefer SNY or TAK?

Do institutionals & insiders hold more shares of SNY or TAK?

Summary

How does Takeda Pharmaceutical compare to GSK?

Does the media favor TAK or GSK?

Is TAK or GSK a better dividend stock?

Which has better valuation and earnings, TAK or GSK?

Which has more volatility and risk, TAK or GSK?

Do analysts prefer TAK or GSK?

Is TAK or GSK more profitable?

Do insiders & institutionals believe in TAK or GSK?

Summary

How does Takeda Pharmaceutical compare to argenex?

Which has higher valuation and earnings, TAK or ARGX?

Do analysts prefer TAK or ARGX?

Does the media refer more to TAK or ARGX?

Which has more risk and volatility, TAK or ARGX?

Do insiders and institutionals hold more shares of TAK or ARGX?

Is TAK or ARGX more profitable?

Summary

How does Takeda Pharmaceutical compare to Teva Pharmaceutical Industries?

Which has stronger valuation & earnings, TAK or TEVA?

Is TAK or TEVA more profitable?

Which has more volatility & risk, TAK or TEVA?

Do analysts rate TAK or TEVA?

Do insiders and institutionals have more ownership in TAK or TEVA?

Does the media refer more to TAK or TEVA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TAK vs. The Competition

Takeda Pharmaceutical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools